Literature DB >> 18936620

Increased C-11 choline uptake in pagetic bone in a patient with coexisting skeletal metastases from prostate cancer.

Giampiero Giovacchini1, Ana Maria Samanes Gajate, Cristina Messa, Ferruccio Fazio.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18936620     DOI: 10.1097/RLU.0b013e318187ee35

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


× No keyword cloud information.
  5 in total

Review 1.  PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.

Authors:  Giampiero Giovacchini; Elisabetta Giovannini; Rossella Leoncini; Mattia Riondato; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-14       Impact factor: 9.236

2.  [¹¹C]Choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy.

Authors:  Giampiero Giovacchini; Elena Incerti; Paola Mapelli; Margarita Kirienko; Alberto Briganti; Giorgio Gandaglia; Francesco Montorsi; Luigi Gianolli; Maria Picchio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-20       Impact factor: 9.236

3.  Imaging features of Paget's disease on 11C choline PET/CT.

Authors:  Cameron E Leitch; Ajit H Goenka; Benjamin M Howe; Stephen M Broski
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-07-15

4.  A multivalent approach of imaging probe design to overcome an endogenous anion binding competition for noninvasive assessment of prostate specific membrane antigen.

Authors:  Guiyang Hao; Amit Kumar; Timothy Dobin; Orhan K Oz; Jer-Tsong Hsieh; Xiankai Sun
Journal:  Mol Pharm       Date:  2013-06-28       Impact factor: 4.939

5.  When to perform positron emission tomography/computed tomography or radionuclide bone scan in patients with recently diagnosed prostate cancer.

Authors:  Carmelo Caldarella; Giorgio Treglia; Alessandro Giordano; Luca Giovanella
Journal:  Cancer Manag Res       Date:  2013-06-25       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.